| Biogen Idec MA Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120100575 | ANTIBODIES HAVING ALTERED EFFECTOR FUNCTION AND METHODS FOR MAKING THE SAME - The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics. | 04-26-2012 |
| 20120100140 | STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE - A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics. | 04-26-2012 |
| 20120087925 | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS - A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1. | 04-12-2012 |
| 20120083453 | TREATMENT USING NEUBLASTIN POLYPEPTIDES - The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides. | 04-05-2012 |
| 20120058125 | METHODS RELATING TO PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES - This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides. | 03-08-2012 |
| 20120058083 | Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta - The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics. | 03-08-2012 |
| 20120027754 | Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6 - The present invention relates to methods of asthma treatment and prevention using α | 02-02-2012 |
| 20120022236 | Recombinant Anti-VLA4 Antibody Molecules - The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation. | 01-26-2012 |
| 20120021484 | Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins - The invention is directed to methods of purifying Fc-containing molecules using a soluble neonatal Fc receptor (sFcRn). Native FcRn binds Fc-containing proteins at or below about pH 6.5 and releases them at or above about pH 7 and provides a much milder approach for capturing and purifying Fc-containing proteins, in particular, therapeutic Fc-containing proteins. Other embodiments of the invention provide modifications to alter the pH for binding and elution to the sFcRn, to modulate Fc-containing protein binding affinity, to affect sFcRn linkage to a support surface, or to improve the stability of sFcRn to conditions utilized in the methods of the invention. | 01-26-2012 |
| 20120020970 | METHODS OF EVALUATING PATIENTS - Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. | 01-26-2012 |
| 20120020913 | METHODS FOR PANCREATIC TISSUE REGENERATION - Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or conditions where enhancement of pancreatic progenitor cells for cell replacement therapy is desirable, including, e g, diabetes and conditions that result in loss of all or part of the pancreas | 01-26-2012 |
| 20120015424 | Arginine Inactivation of Viruses - The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment. | 01-19-2012 |
| 20120014953 | TREATING AND EVALUATING INFLAMMATORY DISORDERS - Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods. | 01-19-2012 |
| 20120003235 | ANTI-LYMPHOTOXIN ANTIBODIES - The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LTβR signaling are also provided. | 01-05-2012 |
| 20120003210 | NEONATAL Fc RECEPTOR (FcRn)- BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO - The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof. | 01-05-2012 |
| 20110311542 | Sp35 Antibodies and Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody | 12-22-2011 |
| 20110305629 | Anti-Alpha v Beta 6 Antibodies and Uses Thereof - The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize α | 12-15-2011 |
| 20110301331 | Stabilized polypeptide compositions - The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules. | 12-08-2011 |
| 20110293512 | Compositions and Methods for Inhibiting Growth of SMAD-4 Deficient Cancers - The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin α | 12-01-2011 |
| 20110287007 | Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6 - The present invention relates to methods of asthma treatment and prevention using α | 11-24-2011 |
| 20110281821 | Modulators of Mitotic Kinases - The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis. | 11-17-2011 |
| 20110250200 | SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided. | 10-13-2011 |
| 20110244501 | CANCER STEM CELLS - Cancer stem cell populations characterized by expression of CD44 | 10-06-2011 |
| 20110243966 | SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject. | 10-06-2011 |
| 20110189177 | ANTIBODIES TO VLA-1 - Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures. | 08-04-2011 |
| 20110158993 | Train-R: A Cysteine Rich Member of the TNF-Receptor Family - Novel receptor in the TNF family: TRAIN-receptor. | 06-30-2011 |
| 20110152260 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase - The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK-mediated or IRAK-associated conditions or diseases. | 06-23-2011 |
| 20110147312 | Automated System And Method For Monitoring Chromatography Column Performance, And Applications Thereof - The present invention provides automated systems and methods for monitoring column performance in process chromatography, and applications thereof. In an embodiment, column performance is monitored by generating a plurality of process values such as, for example, conductivity values or pH values with a detector during a chromatography step transition between a first mobile phase liquid and a second mobile phase liquid. The process values are transformed to form transformed process values in which noise present in the process values is suppressed. Column performance parameters are calculated based on the transformed process values and displayed during movement of the second mobile phase liquid through the chromatography column. The displayed performance parameters enable an operator to make a determination, for example, regarding the quality of the chromatography column packing and whether to continue the chromatography process or stop the chromatography process until the chromatography column can be repacked or replaced. | 06-23-2011 |
| 20110135648 | ANTI-NEUBLASTIN ANTIBODIES AND USES THEREOF - Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity. | 06-09-2011 |
| 20110129468 | PURIFIED IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF THEIR PURIFICATION - The invention provides methods and compositions for separating impurities during the manufacture of immunoglobulin (Ig) fusion proteins. Examples of impurities which may be removed in accordance with the methods of the invention include inactive forms of the Ig fusion protein and/or aggregates. | 06-02-2011 |
| 20110123553 | Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination - The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist. | 05-26-2011 |
| 20110123535 | Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival - The invention provides methods of treating diseases, disorders or injuries involving oligodendrocyte death, demyelination and dysmyelination, including spinal cord injury, by the administration of an NgR1 antagonist. | 05-26-2011 |
| 20110052500 | TAJ in Neuronal Function - The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist. | 03-03-2011 |
| 20110046073 | SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided. | 02-24-2011 |
| 20110021513 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE - The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase. | 01-27-2011 |
| 20110020222 | MODIFIED ANTIBODIES AND METHODS OF USE - Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients. | 01-27-2011 |
| 20110002924 | TWEAK RECEPTOR AGONISTS AS ANTI-ANGIOGENIC AGENTS - The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed. | 01-06-2011 |
| 20100330081 | CRIPTO BINDING MOLECULES - The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof and their use in treating disorders, such as cancer either alone or in combination with other agents. | 12-30-2010 |
| 20100310548 | Methods of Manufacturing a Biologic Using a Stable Storage Intermediate - The present invention is directed to methods of isolating and purifying protein from a bioreactor process. The invention relates to employing a protein phase separation methodology to isolate or purify protein product in the forms of solid, semi-solid, or suspension during a protein manufacturing purification process as a stable storage intermediate. This approach is designed to allow the isolated protein product (purified or partially purified) to be stored over an extended period of time prior to further protein purification steps. | 12-09-2010 |
| 20100303813 | BIOMARKERS FOR PREDICTING ANTI-TNF RESPONSIVENESS OR NON-RESPONSIVENESS - The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder. | 12-02-2010 |
| 20100297121 | Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists - This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist. | 11-25-2010 |
| 20100292142 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 11-18-2010 |
| 20100284933 | Biomarkers of Multiple Sclerosis - Biomarkers of multiple sclerosis (MS) and of anti-TWEAK/TWEAK-Receptor therapy for MS are described. | 11-11-2010 |
| 20100272721 | TREATMENT OF CANCER - Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described. | 10-28-2010 |
| 20100272716 | Antibodies to VLA-1 - Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures. | 10-28-2010 |
| 20100266587 | Compositions and Methods to Treat Acute Myelogenous Leukemia - Compositions and methods for treating or preventing a hematologic malignancy, such as AML, using an anti-alpha4 antibody are described. | 10-21-2010 |
| 20100266542 | RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF - Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed. | 10-21-2010 |
| 20100261654 | COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION - Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject. | 10-14-2010 |
| 20100249067 | Modulators of Mitotic Kinases - The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis. | 09-30-2010 |
| 20100240617 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 09-23-2010 |
| 20100204304 | NOGO Receptor Binding Protein - The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof. | 08-12-2010 |
| 20100203046 | FC GAMMA RECEPTOR-BINDING POLYPEPTIDE VARIANTS AND METHODS RELATED THERETO - The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof. | 08-12-2010 |
| 20100203042 | RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES - The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation. | 08-12-2010 |
| 20100202962 | Cripto blocking antibodies and uses thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications. | 08-12-2010 |
| 20100166741 | ALTERED BR-3 BINDING POLYPEPTIDES - The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 07-01-2010 |
| 20100160258 | Bicyclic aryl sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
| 20100158879 | EXPRESSION CASSETTE AND VECTOR FOR TRANSIENT OR STABLE EXPRESSION OF EXOGENOUS MOLECULES - The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided. | 06-24-2010 |
| 20100150905 | KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS - Compositions and methods for treating Th2- and ThI-mediated disease are provided. | 06-17-2010 |
| 20100136625 | METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION - Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification. | 06-03-2010 |
| 20100136000 | TREATMENT OF FOLLICULAR LYMPHOMAS USING INHIBITORS OF THE LT PATHWAY - Therapeutic uses of inhibitors of the lymphotoxin pathway to treat tumors, specifically to treat follicular lymphomas. | 06-03-2010 |
| 20100127860 | Systems and Methods for Evaluating Chromatography Column Performance - Methods and systems for evaluating and/or monitoring chromatography column performance are provided. Embodiments apply multivariate analysis (MVA) methods to process data as well as transition analysis data to provide a comprehensive evaluation of chromatography column performance. In embodiments, transition analysis data generated over extended periods of time can be analyzed together with process data to evaluate column performance. Further, embodiments enable a compact and robust tool for combining and presenting performance evaluation results, which allows for time-efficient performance examination. According to embodiments, MVA methods applied on transition analysis and process data provide (1) near real-time ability to comprehensively monitor column packing quality; (2) sensitive detection of column integrity breaches; (3) sensitive detection of subtle changes in column packing; (4) sensitive detection of different types of changes in column packing; (5) sensitive detection of fronting/tailing; and (6) sensitive detection of changes in process performance. | 05-27-2010 |
| 20100119511 | LIGHT TARGETING MOLECULES AND USES THEREOF - LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided. | 05-13-2010 |
| 20100105714 | Furanone Compounds and Methods of Making and Using The Same - The invention features compounds of the general Formula (I): (formula should be inserted here) Compounds of Formula (I) possess unexpectedly high affinity for Alk5 and/or Alk4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. | 04-29-2010 |
| 20100104573 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF - This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions. | 04-29-2010 |
| 20100099147 | Anti-IGF-1R Antibodies and Uses Thereof - The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention. | 04-22-2010 |
| 20100098710 | Anti-IGF-1R Antibodies and Uses Thereof - The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention. | 04-22-2010 |
| 20100093980 | Methods of Humanizing Immunoglobulin Variable Regions Through Rational Modification Of Complementarity Determining Residues - The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies. | 04-15-2010 |
| 20100080798 | KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM - The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-γ by lymphocytes or other immune cells in a mammal. Inhibition of IFN-γ is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease. | 04-01-2010 |
| 20100062471 | Biomarkers for Multiple Sclerosis and Methods of Use Thereof - Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients. | 03-11-2010 |
| 20100056440 | COMPOSITIONS AND METHODS FOR ADMINISTERING GDNF LIGAND FAMILY PROTEINS - Disclosed are methods of increasing serum exposure of an administered glial cell line-derived neurotrophic factor (GDNF) ligand family protein by administering to a subject via systemic delivery (i) a GDNF ligand family protein, and (ii) an amount of heparin or heparan sulphate that increases serum exposure of the administered GDNF ligand family protein in the subject. | 03-04-2010 |
| 20100041032 | COMPOSITION AND METHODS FOR THE DETECTION OF CRIPTO-3 - The present invention is based, at least in part, on the discovery that the pseudogene TDGF3 (Cripto-3) is expressed in cells and, in particular, that TDGF3 overexpression is associated with transformation of a cell, e.g., TDGF3 is overexpressed in cancer cell lines and cells from tumor tissue. Accordingly, the invention provides compositions, kits, and methods for detecting the presence of a TDGF3 polynucleotide or polypeptide in a sample. The invention further provides compositions, kits and methods for assessing whether a cell is transformed as well as for assessing whether a patient is a suitable candidate for an anti-Cripto antibody therapy. | 02-18-2010 |
| 20100035918 | Imidazolone Compounds and Methods of Making and Using the Same - In one aspect, the invention features a compound of the general Formula (I). Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. | 02-11-2010 |
| 20090324602 | ANTI-FN14 ANTIBODIES AND USES THEREOF - Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a tumor cell and treat disorders and in a subject. | 12-31-2009 |
| 20090324598 | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS - A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1. | 12-31-2009 |
| 20090312851 | System and Method for Bioprocess Control - A system and method for controlling a bioprocess equipment (FIG. | 12-17-2009 |
| 20090304699 | METHODS OF TREATING FIBROSIS - Methods and compositions for treating fibrosis are disclosed. | 12-10-2009 |
| 20090291088 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS - The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies. | 11-26-2009 |
| 20090286958 | INTERFERON-BETA FUSION PROTEINS AND USES - A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described. | 11-19-2009 |
| 20090286265 | Cripto Blocking Antibodies And Uses Thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications. | 11-19-2009 |
| 20090285818 | Cripto Blocking Antibodies and Uses Thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications. | 11-19-2009 |
| 20090258831 | TREATMENT USING NEUBLASTIN POLYPEPTIDES - The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides. | 10-15-2009 |
| 20090221821 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME - The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A | 09-03-2009 |
| 20090220998 | Platelet Aggregation Assays - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 09-03-2009 |
| 20090215691 | NOGO Receptor Antagonists - Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. | 08-27-2009 |
| 20090202562 | ANTI-GFRALPHA3 ANTIBODIES - Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject. | 08-13-2009 |
| 20090202527 | TREATMENT FOR MULTIPLE SCLEROSIS - Methods of treating multiple sclerosis and other disorders are disclosed. | 08-13-2009 |
| 20090186036 | Anti-Alpha V Beta 6 Antibodies - Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having O06-mediated diseases, or to diagnose % Qmediated diseases. | 07-23-2009 |
| 20090175862 | COMBINATION THERAPY EMPLOYING LYMPHOTOXIN BETA RECEPTOR BINDING MOLECULES IN COMBINATION WITH SECOND AGENTS - This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other biologic agents, as well as therapeutic methods. | 07-09-2009 |
| 20090175846 | Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof - The present invention is based on the discovery that oligodendrocyte-myelin glycoprotein (OMgp), which is ex-pressed by oligodendrocytes and CNS myelin, negatively regulates oligodendrocyte and neuronal differentiation and survival. Based on these discoveries, the invention relates generally to methods of promoting neuronal and oligodendrocyte survival and differentiation by administration of an OMgp anatagonist. Additionally, the invention generally relates to methods of treating various diseases, disorders or injuries associated with demyelination, dysmyelination, oligodendrocyte/neuronal cell death, axonal injury and/or differentiation by the administration of an OMgp antagonist. | 07-09-2009 |
| 20090155255 | CD23 BINDING MOLECULES AND METHODS OF USE THEREOF - The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL. | 06-18-2009 |
| 20090130105 | COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R - The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-1R, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-1R signaling are also provided. | 05-21-2009 |
| 20090123421 | ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS - This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-a/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity. | 05-14-2009 |
| 20090092614 | Anti-IGF-1R Antibodies and Uses Thereof - The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies capable of synergistically inhibiting the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2), to bind to IGF-1R; as well as fragments, variants and derivatives of such antibodies. Antibodies of the invention produce such synergistic effects via allosteric and/or competitive inhibition of IGF-1R ligand binding. | 04-09-2009 |
| 20090092601 | HUMANIZED ANTI-LT-beta-R ANTIBODIES - Humanized antibodies to LT-β-R and methods of use thereof are provided. | 04-09-2009 |
| 20090068102 | TREATING STROKE - Methods of treating stroke with blocking agents of TWEAK or TWEAK receptor are presented. | 03-12-2009 |
| 20090062199 | Nogo Receptor Polypeptides and Polypeptide Fragments and Uses Thereof - Nogo receptor 1 (NgR1) is a leucine rich repeat protein that forms part of a signaling complex that modulates axon regeneration. Previous studies have shown that the entire LRR region of Nogo receptor-1, including the C-terminal cap of LRR, LRRCT, is needed for ligand binding, and that the adjacent CT stalk of the Nogo receptor-1 contributes to interaction with its co-receptors. The present invention is directed to the use of certain Nogo receptor-1 and Nogo receptor-2 polypeptides and polypeptide fragments for promoting neurite outgrowth, neuronal survival, and axonal regeneration in CNS neurons. The invention features molecules and methods useful for inhibiting neurite outgrowth inhibition, promoting neuronal survival, and/or promoting axonal regeneration in CNS neurons. | 03-05-2009 |
| 20090054632 | Hydrophobically-modified protein compositions and methods - Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle. | 02-26-2009 |
| 20090053227 | Prostate Specific Genes and The Use Thereof in Design of Therapeutics - Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2. | 02-26-2009 |
| 20090048122 | Stabilized polypeptide compositions - The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules. | 02-19-2009 |
| 20090047737 | Human LY6-Big Molecules and Methods of Use - The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of such cancers, and in diagnostic, prognostic, and treatment methods for autoimmune disorders and AIDS. | 02-19-2009 |
| 20090041758 | MODIFIED BINDING MOLECULES COMPRISING CONNECTING PEPTIDES - The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention. | 02-12-2009 |
| 20090028853 | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6 - The present invention relates to methods of asthma treatment and prevention using α | 01-29-2009 |
| 20090017044 | Antibodies to the Human Prolactin Receptor - This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids. | 01-15-2009 |
| 20090010930 | ANTIBODIES TO VLA-1 - Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures. | 01-08-2009 |
| 20090004188 | Train R: A Cysteine Rich Member of the TNF-Receptor Family - Novel receptor in the TNF family: TRAIN-receptor. | 01-01-2009 |
| 20080317667 | Compositions and methods for inhibiting growth of smad4-deficient cancers - The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin α | 12-25-2008 |
| 20080311119 | ANTIBODY FORMULATIONS - Formulations of VLA-4 binding antibody are described. | 12-18-2008 |
| 20080306212 | POLYMER CONJUGATES OF MUTATED NEUBLASTIN - A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin. | 12-11-2008 |
| 20080305116 | Anti-Cd154 Antibodies - The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject. | 12-11-2008 |
| 20080299042 | Membrane Associated Molecules - The present invention is directed to novel methods of treating, identifying or diagnosing a hyperproliferative disorder in a patient in need thereof. The methods of the invention include administering to a patient a composition comprising a binding molecule which binds to a cell surface expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding molecule, for example an antibody or immunospecific fragment thereof, which specifically binds to a membrane associated molecule, variant polypeptide or fragment thereof. The present invention is based, at least in part, on the discovery of membrane associated proteins, i.e., nucleic acid molecules which encode membrane proteins and the use of these molecules to generate custom arrays to screen for markers associated with various diseases and disorders, e.g., cancer, e.g., lung, colon, pancreatic and ovarian cancer and autoimmune diseases or disorders. The invention further relates to various methods, reagents and kits for diagnosing, staging, prognosing, monitoring and treating hyperproliferative diseases or disorders such as cancer, e.g., lung, colon, pancreatic and ovarian cancer and autoimmune diseases or disorders. | 12-04-2008 |
| 20080292622 | METHODS OF EVALUATING PATIENTS - Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. | 11-27-2008 |
| 20080279853 | TREATMENT OF CANCER - Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described. | 11-13-2008 |
| 20080262795 | Process Equipment Monitoring - A system and method for monitoring process equipment includes collecting information from the process equipment. The collected information is statistically analyzed. One or more signatures indicating the overall status or health of one or more pieces of equipment can be developed. | 10-23-2008 |
| 20080260728 | Treatment of Severe Multiple Sclerosis - Methods of treating multiple sclerosis are disclosed. | 10-23-2008 |
| 20080249287 | Refolding Transforming Growth Factor Beta Family Proteins - Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product. | 10-09-2008 |
| 20080241163 | TWEAK BINDING ANTIBODIES - Anti-Tweak antibodies are described. | 10-02-2008 |
| 20080234271 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them - The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject. | 09-25-2008 |
| 20080233647 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 09-25-2008 |
| 20080219967 | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases - Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. | 09-11-2008 |
